Alex Zwiers

443 total citations
15 papers, 335 citations indexed

About

Alex Zwiers is a scholar working on Anesthesiology and Pain Medicine, Developmental Neuroscience and Critical Care and Intensive Care Medicine. According to data from OpenAlex, Alex Zwiers has authored 15 papers receiving a total of 335 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Anesthesiology and Pain Medicine, 5 papers in Developmental Neuroscience and 4 papers in Critical Care and Intensive Care Medicine. Recurrent topics in Alex Zwiers's work include Anesthesia and Sedative Agents (8 papers), Anesthesia and Neurotoxicity Research (5 papers) and Intensive Care Unit Cognitive Disorders (4 papers). Alex Zwiers is often cited by papers focused on Anesthesia and Sedative Agents (8 papers), Anesthesia and Neurotoxicity Research (5 papers) and Intensive Care Unit Cognitive Disorders (4 papers). Alex Zwiers collaborates with scholars based in Netherlands, United Kingdom and United States. Alex Zwiers's co-authors include Jean Smeets, Samantha Rutherford, Pierre Peeters, Paul Passier, Michiel W. van den Heuvel, Thijs van Iersel, Judith P. ter Horst, Diels van den Dobbelsteen, Sjoerd van Marle and Fabiany da Costa Gonçalves and has published in prestigious journals such as Human Gene Therapy, Thrombosis Research and European Journal of Anaesthesiology.

In The Last Decade

Alex Zwiers

14 papers receiving 322 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alex Zwiers Netherlands 8 225 101 96 56 45 15 335
R. Hoernecke Germany 12 208 0.9× 96 1.0× 42 0.4× 58 1.0× 41 0.9× 24 430
Matthew R. Belmont United States 11 456 2.0× 216 2.1× 134 1.4× 94 1.7× 61 1.4× 25 531
F. Hope Netherlands 9 286 1.3× 138 1.4× 162 1.7× 90 1.6× 42 0.9× 11 357
Daniel P. Lynam United States 9 293 1.3× 140 1.4× 73 0.8× 91 1.6× 28 0.6× 18 383
Diane Bitzinger Germany 11 28 0.1× 39 0.4× 42 0.4× 60 1.1× 69 1.5× 29 326
Di Qiu China 9 57 0.3× 31 0.3× 41 0.4× 52 0.9× 88 2.0× 23 311
Mir A. Hashim United States 8 82 0.4× 46 0.5× 28 0.3× 8 0.1× 72 1.6× 18 189
Parisa Partownavid United States 6 54 0.2× 132 1.3× 32 0.3× 8 0.1× 27 0.6× 14 244
Xianying Lei China 6 72 0.3× 45 0.4× 22 0.2× 48 0.9× 40 0.9× 17 198
Yi‐Hsuan Huang Taiwan 10 68 0.3× 67 0.7× 75 0.8× 9 0.2× 34 0.8× 28 261

Countries citing papers authored by Alex Zwiers

Since Specialization
Citations

This map shows the geographic impact of Alex Zwiers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alex Zwiers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alex Zwiers more than expected).

Fields of papers citing papers by Alex Zwiers

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alex Zwiers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alex Zwiers. The network helps show where Alex Zwiers may publish in the future.

Co-authorship network of co-authors of Alex Zwiers

This figure shows the co-authorship network connecting the top 25 collaborators of Alex Zwiers. A scholar is included among the top collaborators of Alex Zwiers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alex Zwiers. Alex Zwiers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
2.
Zwiers, Alex, et al.. (2023). Clinical development time is shorter for new anticancer drugs approved via accelerated approval in the US or via conditional approval in the EU. Clinical and Translational Science. 16(7). 1127–1133. 7 indexed citations
3.
Meijers, Joost C.M., Kamran Bakhtiari, Alex Zwiers, & Stephan L.M. Peters. (2023). OKL-1111, A modified cyclodextrin as a potential universal reversal agent for anticoagulants. Thrombosis Research. 227. 17–24. 6 indexed citations
4.
Gonçalves, Fabiany da Costa, et al.. (2022). A detailed analysis of expedited regulatory review time of marketing authorization applications for new anticancer drugs in the US and EU. Clinical and Translational Science. 15(8). 1959–1967. 10 indexed citations
5.
Horst, Judith P. ter, et al.. (2021). Implementation of Quality by Design (QbD) Principles in Regulatory Dossiers of Medicinal Products in the European Union (EU) Between 2014 and 2019. Therapeutic Innovation & Regulatory Science. 55(3). 583–590. 34 indexed citations
6.
Steenhof, Maaike, et al.. (2021). A Decade of Marketing Authorization Applications of Anticancer Drugs in the European Union: An Analysis of Procedural Timelines. Therapeutic Innovation & Regulatory Science. 55(4). 633–642. 7 indexed citations
7.
Zwiers, Alex, et al.. (2021). Healthy Volunteer Studies in the Development of Anticancer Drugs with Genotoxic Findings. Therapeutic Innovation & Regulatory Science. 56(1). 76–84. 1 indexed citations
8.
Kam, Pieter‐Jan de, Martijn P. van den Heuvel, Peter Grobara, et al.. (2011). Flucloxacillin and Diclofenac do not Cause Recurrence of Neuromuscular Blockade after Reversal with Sugammadex. Clinical Drug Investigation. 32(3). 203–212. 9 indexed citations
9.
Peeters, Pierre, Paul Passier, Jean Smeets, et al.. (2011). Sugammadex is cleared rapidly and primarily unchanged via renal excretion. Biopharmaceutics & Drug Disposition. 32(3). 159–167. 46 indexed citations
10.
Zwiers, Alex, et al.. (2011). Assessment of the Potential for Displacement Interactions with Sugammadex. Clinical Drug Investigation. 31(2). 101–111. 61 indexed citations
11.
Peeters, Pierre, Michiel W. van den Heuvel, Paul Passier, et al.. (2010). Safety, Tolerability and Pharmacokinetics of Sugammadex Using Single High Doses (Up to 96 mg/kg) in Healthy Adult Subjects. Clinical Drug Investigation. 30(12). 867–874. 53 indexed citations
12.
Zwiers, Alex, et al.. (2010). Assessment of the Potential for Displacement Interactions with Sugammadex. Clinical Drug Investigation. 31(2). 1–1. 41 indexed citations
13.
Peeters, Pierre, Michiel W. van den Heuvel, Paul Passier, et al.. (2010). Safety, Tolerability and Pharmacokinetics of Sugammadex Using Single High Doses (Up to 96 mg/kg) in Healthy Adult Subjects. Clinical Drug Investigation. 1–1. 50 indexed citations
14.
15.
Peeters, P. A. M., Paul Passier, Jean Smeets, Thijs van Iersel, & Alex Zwiers. (2008). Single intravenous high-dose sugammadex (up to 96 mg/kg) is generally safe and well tolerated in healthy volunteers. European Journal of Anaesthesiology. 25(Sup 44). 132–132. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R. Hoernecke Breakdown of academic impact, for papers by Matthew R. Belmont Breakdown of academic impact, for papers by F. Hope Breakdown of academic impact, for papers by Daniel P. Lynam Breakdown of academic impact, for papers by Diane Bitzinger Breakdown of academic impact, for papers by Di Qiu Breakdown of academic impact, for papers by Mir A. Hashim Breakdown of academic impact, for papers by Parisa Partownavid Breakdown of academic impact, for papers by Xianying Lei Breakdown of academic impact, for papers by Yi‐Hsuan Huang
Rankless by CCL
2026